Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.
Also called NCT04013581
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 121 participants
- Sponsor
- Registry
-
NCT04013581
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04013581. Randomized; no masking; primary purpose treatment. Start 2019-08-05 (actual); primary completion 2020-05-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- TZD group
- Intervention (Drug)
- SGLT-2 group
- Lead sponsor
- Yonsei University
Record details
- Record id
cardio:ct-nct04013581- Content hash
44ad9fe628e2d3031388305ba4f83029fec4cc726ec697541690a675e8638387